Diazoxide

二氮嗪

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameDiazoxide
Drug Alias Namediazoxidum二氮嗦氯苯甲噻二嗪diazoxide降压嗪 +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsPotassium channel agonists
TargetsPotassium channel
Therapy Area/IndicationsDepressionObesityHypoglycemia +[11] 
Global Approved IndicationsHypoglycemiaHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1973/01/22
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesJohns Hopkins UniversityColumbia UniversityTeva Branded Pharmaceutical Products R&D Inc +[4] 
Inactive CompaniesSchering AgUniversity Of SaskatchewanNational Institute Of Mental Health (Nimh)
Active IndicationsObesityInsulin ResistanceHyperinsulinism +[7] 
Inactive IndicationsDepressionHypoglycemiaInfant, Newborn, Diseases +[4] 

Other Information

ATC CodeC02DA01V03AH01
Related LinksWikipediaDrugBankKEGG